{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:48:35Z","timestamp":1777132115216,"version":"3.51.4"},"reference-count":262,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271837"],"award-info":[{"award-number":["82271837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.autrev.2026.104039","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T16:26:33Z","timestamp":1774023993000},"page":"104039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chinese recommendations for the diagnosis and management of non-radiographic axial spondyloarthritis"],"prefix":"10.1016","volume":"25","author":[{"given":"Sheng-Ming","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104039_bb0005","doi-asserted-by":"crossref","unstructured":"Braun J, Sieper J. Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. Ann Rheum Dis. 2002;61 Suppl 3:iii61-7. doi:10.1136\/ard.61.suppl_3.iii61.","DOI":"10.1136\/ard.61.suppl_3.iii61"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195602000-00001","article-title":"The natural history of rheumatoid spondylitis","volume":"35","author":"Blumberg","year":"1956","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.1780070113","article-title":"Ara nomenclature and classification of arthritis and rheumatism (tentative)","volume":"7","author":"Blumberg","year":"1964","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00005792-197409000-00002","article-title":"Associations between ankylosing spondylitis, psoriatic arthritis, Reiter\u2019s disease, the intestinal arthropathies, and Behcet\u2019s syndrome","volume":"53","author":"Moll","year":"1974","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00296-002-0237-4","article-title":"Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis","volume":"23","author":"Feldtkeller","year":"2003","journal-title":"Rheumatol Int"},{"issue":"9313","key":"10.1016\/j.autrev.2026.104039_bb0035","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"10089","key":"10.1016\/j.autrev.2026.104039_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0045","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.20990","article-title":"The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?","volume":"52","author":"Rudwaleit","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/ard.2003.011247","article-title":"How to diagnose axial spondyloarthritis early","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.autrev.2026.104039_bb0055","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029063","article-title":"Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease: a narrative review","volume":"101","author":"Magrey","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection [published correction appears in Ann Rheum Dis. 2019 Jun;78(6):e59]","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.rdc.2012.08.011","article-title":"Imaging in axial spondyloarthritis: diagnostic problems and pitfalls","volume":"38","author":"Baraliakos","year":"2012","journal-title":"Rheum Dis Clin N Am"},{"issue":"Suppl1","key":"10.1016\/j.autrev.2026.104039_bb0070","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31138\/mjr.33.1.109","article-title":"Pearls and pitfalls in diagnosing non-radiographic axial spondyloarthritis","volume":"33","author":"Tsiami","year":"2022","journal-title":"Mediterr J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105468","article-title":"Challenges in non-radiographic axial spondyloarthritis","volume":"90","author":"Poddubnyy","year":"2023","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0080","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2023.101871","article-title":"Challenges in the diagnosis of axial spondyloarthritis","volume":"37","author":"van Gaalen","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0090","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/rheumatology\/kead532","article-title":"Why are the classification and diagnosis of axial spondyloarthritis sometimes so difficult?","volume":"63","author":"Braun","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-022-01096-0","article-title":"Axial spondyloarthritis and diagnostic challenges: over-diagnosis, misdiagnosis, and under-diagnosis","volume":"25","author":"Bittar","year":"2023","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004484","article-title":"Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort","volume":"10","author":"Molto","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000586","article-title":"MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations \u2018Not everything that glisters is gold (standard)\u2019","volume":"4","author":"Lukas","year":"2018","journal-title":"RMD Open"},{"issue":"Suppl4","key":"10.1016\/j.autrev.2026.104039_bb0110","doi-asserted-by":"crossref","first-page":"iv6","DOI":"10.1093\/rheumatology\/keaa250","article-title":"Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis","volume":"59","author":"Poddubnyy","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12891-022-05073-7","article-title":"Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review","volume":"23","author":"Mease","year":"2022","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0120","first-page":"29","article-title":"Are we overcalling sacroiliitis on MRI? Differential diagnosis that every rheumatologist should know - Part I","volume":"44","author":"Campos-Correia","year":"2019","journal-title":"Acta Reumatol Port"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0125","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0140","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39666","article-title":"Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis","volume":"68","author":"Dougados","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0145","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/art.39542","article-title":"Progression of nonradiographic axial spondyloarthritis to ankylosing spondylitis: a population-based cohort study","volume":"68","author":"Wang","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0150","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/rheumatology\/key387","article-title":"Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts","volume":"58","author":"Sepriano","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0155","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/ard-2023-225184","article-title":"Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort","volume":"83","author":"Molto","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2017-212178","article-title":"An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS","volume":"77","author":"Molto","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0170","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0175","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ard.2009.111187","article-title":"Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors","volume":"69","author":"Pedersen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0180","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/annrheumdis-2012-201999","article-title":"MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor","volume":"71","author":"Machado","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0185","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keaa564","article-title":"Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors","volume":"60","author":"Sepriano","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0190","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0195","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1136\/annrheumdis-2016-209209","article-title":"High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort","volume":"75","author":"Poddubnyy","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0200","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","article-title":"Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis","volume":"19","author":"Bautista-Molano","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0205","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/ard.2010.128462","article-title":"\u2018Treat to target\u2019: moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis","volume":"69","author":"Atar","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0215","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/acr.25408","article-title":"Barriers to, facilitators of, and interventions to support treat-to-target implementation in rheumatoid arthritis: a systematic review","volume":"76","author":"Gossec","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0220","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/annrheumdis-2021-220603","article-title":"What is the optimal target for a T2T approach in axial spondyloarthritis?","volume":"80","author":"Sieper","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0225","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/BOR.0000000000000941","article-title":"Go or no-go for treat-to-target in axial spondyloarthritis?","volume":"35","author":"Webers","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/kead155","article-title":"Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target","volume":"63","author":"Bolt","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0235","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/annrheumdis-2012-201403","article-title":"The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10","volume":"72","author":"Weisman","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103405","article-title":"A strategy towards disentangling treatment refractory from misdiagnosed axial Spondyloarthritis","volume":"23","author":"McGonagle","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0250","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1093\/rheumatology\/keab242","article-title":"Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0255","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","article-title":"Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers\u2019 effectiveness in axial spondyloarthritis: results of a prospective, multicentre study","volume":"77","author":"Molt\u00f3","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0260","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1093\/rheumatology\/keaa768","article-title":"Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0265","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/art.38776","article-title":"The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration\u2019s comments and concerns","volume":"66","author":"Deodhar","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0270","first-page":"526","article-title":"A new drug in treatment of radiographically negative axial spondyloarthritis: certolizumab pegol","volume":"39","author":"Luo","year":"2020","journal-title":"Chinese J N Drugs Clin Remedies"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0275","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/art.37803","article-title":"Nonradiographic axial spondyloarthritis: new definition of an old disease?","volume":"65","author":"Sieper","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0285","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/art.24483","article-title":"The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort","volume":"60","author":"Rudwaleit","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0290","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keq129","article-title":"Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis","volume":"49","author":"Braun","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0295","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/art.1780331202","article-title":"Magnetic resonance imaging of sacroiliac joint inflammation","volume":"33","author":"Ahlstr\u00f6m","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004728-199601000-00013","article-title":"A comparison of MR and CT in suspected sacroiliitis","volume":"20","author":"Wittram","year":"1996","journal-title":"J Comput Assist Tomogr"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0305","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1034\/j.1600-0455.2003.00034.x","article-title":"Imaging of sacroiliitis in early seronegative spondylarthropathy. Assessment of abnormalities by MR in comparison with radiography and CT","volume":"44","author":"Puhakka","year":"2003","journal-title":"Acta Radiol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0310","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/rheumatology\/ket012","article-title":"Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence","volume":"52","author":"de Hooge","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0315","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00330-015-3790-4","article-title":"Optimizing the MRI protocol of the sacroiliac joints in Spondyloarthritis: which para-axial sequence should be used?","volume":"26","author":"Giraudo","year":"2016","journal-title":"Eur Radiol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0320","first-page":"1953","article-title":"Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study","volume":"26","author":"Oostveen","year":"1999","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0325","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1002\/art.24024","article-title":"Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years","volume":"58","author":"Bennett","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0330","doi-asserted-by":"crossref","first-page":"271","DOI":"10.23736\/S1824-4785.17.02981-8","article-title":"Role for imaging in spondyloarthritis","volume":"61","author":"Ran","year":"2017","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0335","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2016-210640","article-title":"Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study","volume":"76","author":"Diekhoff","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0340","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3899\/jrheum.130141","article-title":"Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis","volume":"40","author":"Poddubnyy","year":"2013","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0345","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","article-title":"Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0350","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","article-title":"Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group","volume":"75","author":"Lambert","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0355","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2019-215589","article-title":"MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group","volume":"78","author":"Maksymowych","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(25)00319-4","article-title":"An imaging crisis in axial spondyloarthritis","volume":"8","author":"Abudayeh","year":"2026","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0365","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/1756-185X.13125","article-title":"Osteitis condensans ilii may demonstrate bone marrow edema on sacroiliac joint magnetic resonance imaging","volume":"21","author":"Ma","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0370","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1093\/rheumatology\/keaa175","article-title":"Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis","volume":"59","author":"Poddubnyy","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0375","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40475","article-title":"Magnetic resonance imaging of the sacroiliac joints indicating sacroiliitis according to the assessment of spondyloarthritis international society definition in healthy individuals, runners, and women with postpartum back pain","volume":"70","author":"de Winter","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0380","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.2214\/AJR.17.19404","article-title":"Postpartum bone marrow edema at the sacroiliac joints may mimic sacroiliitis of axial spondyloarthritis on MRI","volume":"211","author":"Agten","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0385","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00256-020-03700-9","article-title":"Influence of pregnancy\/childbirth on long-term bone marrow edema and subchondral sclerosis of sacroiliac joints","volume":"50","author":"Germann","year":"2021","journal-title":"Skeletal Radiol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0390","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/art.41037","article-title":"Magnetic resonance imaging of lesions in the sacroiliac joints for differentiation of patients with axial spondyloarthritis from control subjects with or without pelvic or buttock pain: a prospective, cross-sectional study of 204 participants","volume":"71","author":"Seven","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0395","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/acr.24473","volume":"73","author":"Seven","year":"2021","journal-title":"Arthritis Care Res"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0400","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/annrheumdis-2020-217208","article-title":"MRI of sacroiliac joints for the diagnosis of axial SpA: prevalence of inflammatory and structural lesions in nulliparous, early postpartum and late postpartum women","volume":"79","author":"Hoballah","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0405","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/annrheumdis-2019-215553","article-title":"Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years","volume":"79","author":"Baraliakos","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0410","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2020-218669","article-title":"Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?","volume":"80","author":"Baraliakos","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0415","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/art.40429","article-title":"Frequency and anatomic distribution of magnetic resonance imaging features in the sacroiliac joints of young athletes: exploring \u201cbackground noise\u201d toward a data-driven definition of sacroiliitis in early spondyloarthritis","volume":"70","author":"Weber","year":"2018","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0420","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/rheumatology\/kex491","article-title":"Effect of mechanical stress on magnetic resonance imaging of the sacroiliac joints: assessment of military recruits by magnetic resonance imaging study","volume":"57","author":"Varkas","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0425","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11596-016-1593-8","article-title":"Human brucellosis mimicking axial spondyloarthritis: a challenge for rheumatologists when applying the 2009 ASAS criteria","volume":"36","author":"Ye","year":"2016","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0430","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s10067-019-04481-w","article-title":"When brucellosis met the Assessment of SpondyloArthritis international Society classification criteria for spondyloarthritis: a comparative study","volume":"38","author":"Wang","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0435","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/acr.21893","article-title":"Development and validation of a magnetic resonance imaging reference criterion for defining a positive sacroiliac joint magnetic resonance imaging finding in spondyloarthritis","volume":"65","author":"Weber","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0440","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12967-021-02959-3","article-title":"MRI contributes to accurate and early diagnosis of non-radiographic HLA-B27 negative axial spondyloarthritis","volume":"19","author":"Lu","year":"2021","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0445","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13075-017-1342-9","article-title":"MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation","volume":"19","author":"Maksymowych","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0450","first-page":"202","article-title":"How sensitive and specific are MRI features of sacroiliitis for diagnosis of spondyloarthritis in patients with inflammatory back pain?","volume":"97","author":"Jans","year":"2014","journal-title":"JBR-BTR"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0455","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/annrheumdis-2016-209405","article-title":"Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort","volume":"76","author":"Bakker","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0460","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3899\/jrheum.130568","article-title":"Fat infiltration on magnetic resonance imaging of the sacroiliac joints has limited diagnostic utility in nonradiographic axial spondyloarthritis","volume":"41","author":"Weber","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0465","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/annrheumdis-2013-203887","article-title":"Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?","volume":"74","author":"Weber","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0470","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1136\/annrheumdis-2015-207823","article-title":"Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?","volume":"75","author":"de Hooge","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0475","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.38283","article-title":"Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis","volume":"66","author":"van der Heijde","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0480","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2214\/ajr.136.1.41","article-title":"CT of sacroiliitis","volume":"136","author":"Carrera","year":"1981","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0485","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.1780241205","article-title":"Computed tomography in the diagnosis of sacroiliitis","volume":"24","author":"Kozin","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0490","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00004728-198204000-00015","article-title":"The sacroiliac joints: anatomic, plain roentgenographic, and computed tomographic analysis","volume":"6","author":"Lawson","year":"1982","journal-title":"J Comput Assist Tomogr"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0495","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/art.1780260609","article-title":"The radiographic diagnosis of sacroiliitis. A comparison of different views with computed tomograms of the sacroiliac joint","volume":"26","author":"Ryan","year":"1983","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0500","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/art.1780280813","article-title":"Computed tomography in the diagnosis of early ankylosing spondylitis","volume":"28","author":"Fam","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0505","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001656","article-title":"CT-like images of the sacroiliac joint generated from MRI using susceptibility-weighted imaging (SWI) in patients with axial spondyloarthriti","volume":"7","author":"Deppe","year":"2021","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0510","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/annrheumdis-2021-220136","article-title":"Choose wisely: imaging for diagnosis of axial spondyloarthritis","volume":"81","author":"Diekhoff","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0515","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s10067-019-04824-7","article-title":"MRI compared with low-dose CT scanning in the diagnosis of axial spondyloarthritis","volume":"39","author":"Ye","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0520","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/1756-185X.12381","article-title":"Evaluation of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis in Chinese patients with chronic back pain: results of a 2-year follow-up study","volume":"17","author":"Lin","year":"2014","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0525","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/ket164","article-title":"Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort","volume":"52","author":"van den Berg","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0530","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/rheumatology\/ket359","article-title":"Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme","volume":"53","author":"Tomero","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0535","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/art.39612","article-title":"Frequency of axial spondyloarthritis diagnosis among patients seen by US rheumatologists for evaluation of chronic back pain","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104039_bb0540","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/acr.21994","article-title":"Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis","volume":"65","author":"Strand","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0545","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/acr.22016","volume":"65","author":"Molt\u00f3","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0550","first-page":"797","article-title":"Evaluation of the predictive validity of the ASAS axial spondyloarthritis criteria in the DESIR cohort","volume":"37","author":"Meghnathi","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0555","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/annrheumdis-2016-210747","article-title":"Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis","volume":"76","author":"Sepriano","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0560","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/acr.22583","article-title":"Distinctions between diagnostic and classification criteria?","volume":"67","author":"Aggarwal","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0565","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10067-007-0727-6","article-title":"Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria","volume":"27","author":"Dincer","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0570","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1136\/annrheumdis-2017-211596","article-title":"Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort","volume":"76","author":"Dougados","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0575","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1136\/ard.2010.145995","article-title":"Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0580","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/rheumatology\/kew496","article-title":"Radiographic sacroiliitis develops predictably over time in a cohort of familial spondyloarthritis followed longitudinally","volume":"56","author":"Costantino","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0585","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/acr2.11642","article-title":"Radiographic progression in sacroiliac joints in patients with Axial Spondyloarthritis: results from a five-year international observational study","volume":"6","author":"Poddubnyy","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0590","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001867","article-title":"Risk factors for progression of juvenile-onset non-radiographic axial spondyloarthritis to juvenile-onset ankylosing spondylitis: a nested case-control study","volume":"7","author":"Li","year":"2021","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0595","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288153","article-title":"Disease course of non-radiographic axial spondyloarthritis: data from a long-term retrospective observational cohort","volume":"18","author":"Kwon","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0600","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/annrheumdis-2017-212008","article-title":"Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis","volume":"77","author":"Dougados","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0605","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.33453","article-title":"Ten years\u2019 experience with needle biopsy in the early diagnosis of sacroiliitis","volume":"64","author":"Gong","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0610","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","article-title":"European League Against Rheumatism (EULAR). EULAR recommendations for patient education for people with inflammatory arthritis","volume":"74","author":"Zangi","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0615","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","article-title":"2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis","volume":"80","author":"Nikiphorou","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0620","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/rheumatology\/keaa480","article-title":"Evaluation of the impact of a nurse-led program of patient self-assessment and self-management in axial spondyloarthritis: results of a prospective, multicentre, randomized, controlled trial (COMEDSPA)","volume":"60","author":"Molto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0625","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0630","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","article-title":"2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis","volume":"77","author":"Rausch Osthoff","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0635","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","article-title":"2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases","volume":"82","author":"Gwinnutt","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0640","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3390\/jfmk8040140","article-title":"The effects of pilates exercise training combined with walking on cardiorespiratory fitness, functional capacity, and disease activity in patients with non-radiologically confirmed axial spondylitis","volume":"8","author":"Zaggelidou","year":"2023","journal-title":"J Funct Morphol Kinesiol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0645","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-016-1180-1","article-title":"Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis","volume":"18","author":"Levitova","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0650","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10067-017-3802-7","article-title":"Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis","volume":"38","author":"Husakova","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0655","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002168","volume":"8","author":"Gwinnutt","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0660","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0665","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00296-014-2965-7","article-title":"Exercise therapy for spondyloarthritis: a systematic review","volume":"34","author":"O\u2019Dwyer","year":"2014","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0670","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.apmr.2017.07.015","article-title":"Effectiveness of exercise programs in Ankylosing Spondylitis: a meta-analysis of randomized controlled trials","volume":"99","author":"P\u00e9courneau","year":"2018","journal-title":"Arch Phys Med Rehabil"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0675","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2015.08.003","article-title":"Exercise for ankylosing spondylitis: an evidence-based consensus statement","volume":"45","author":"Millner","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb0680","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00296-017-3829-8","article-title":"The role of land and aquatic exercise in ankylosing spondylitis: a systematic review","volume":"37","author":"Z\u00e3o","year":"2017","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0685","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019229","article-title":"The comparative efficacy of supervised- versus home-based exercise programs in patients with ankylosing spondylitis: a meta-analysis","volume":"99","author":"Liang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0690","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","article-title":"Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis","volume":"64","author":"Poddubnyy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0695","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/art.41408","article-title":"Do smoking and socioeconomic factors influence imaging outcomes in axial spondyloarthritis? Five-year data from the DESIR cohort","volume":"72","author":"Nikiphorou","year":"2020","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0700","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000153","article-title":"Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis","volume":"1","author":"Ramiro","year":"2015","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0705","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","article-title":"Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort","volume":"71","author":"Chung","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104039_bb0710","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fmed.2019.00214","article-title":"Non-steroidal anti-inflammatory drugs are unlikely to inhibit radiographic progression of Ankylosing Spondylitis: a systematic review","volume":"6","author":"Zhang","year":"2019","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0715","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/kew367","article-title":"Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis","volume":"56","author":"Baraliakos","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0720","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/art.39474","article-title":"Six-week treatment of axial spondyloarthritis patients with an optimal dose of nonsteroidal antiinflammatory drugs: early response to treatment in signal intensity on magnetic resonance imaging of the sacroiliac joints","volume":"68","author":"Varkas","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0725","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10067-017-3666-x","article-title":"Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients","volume":"37","author":"Tang","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0730","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3899\/jrheum.150721","article-title":"Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a cochrane review","volume":"43","author":"Kroon","year":"2016","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0735","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/art.23606","article-title":"Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two","volume":"58","author":"Haibel","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0740","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0745","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","article-title":"Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)","volume":"72","author":"Sieper","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0750","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0755","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0760","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0765","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0770","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/acr2.11312","article-title":"The effect of etanercept in nonradiographic axial spondyloarthritis by stratified C-reactive protein levels","volume":"3","author":"Tam","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb0775","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb0780","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early nonradiographic axial spondyloarthritis: 104-week results from a randomized, placebo-controlled study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0785","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0790","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keab346","article-title":"Long-term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension","volume":"61","author":"van der Heijde","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0795","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13075-021-02428-8","article-title":"Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR","volume":"23","author":"Maksymowych","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0800","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1093\/rheumatology\/kew230","article-title":"Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics","volume":"55","author":"Sieper","year":"2016","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0805","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0810","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000536601","article-title":"Efficacy of TNF-alpha inhibitors in the treatment of nr-axSpA: a systematic review and meta-analysis based on randomized controlled trials","volume":"185","author":"Shentu","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0815","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled Phase III Study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0820","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13075-021-02613-9","article-title":"Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT","volume":"23","author":"Braun","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2026.104039_bb0825","doi-asserted-by":"crossref","unstructured":"Poddubnyy D, Pournara E, Zieli\u0144ska A, Baranauskaite A, Jim\u00e9nez AM, Sadhu S, Schulz B, Rissler M, Perella C, Marzo-Ortega H. Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Ther Adv Musculoskelet Dis. 2021;13:1759720X211051471. doi:10.1177\/1759720X211051471.","DOI":"10.1177\/1759720X211051471"},{"issue":"10217","key":"10.1016\/j.autrev.2026.104039_bb0830","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0835","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1016\/S2665-9913(22)00185-0","article-title":"Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis","volume":"4","author":"Maksymowych","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0840","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002165","article-title":"Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST","volume":"8","author":"Braun","year":"2022","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0845","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0850","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0855","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0860","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0865","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/rheumatology\/keac522","article-title":"Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104039_bb0870","doi-asserted-by":"crossref","unstructured":"Ramonda R, Lorenzin M, Sole Chimenti M, D'Angelo S, Marchesoni A, Salvarani C, Lubrano E, Costa L, Dal Bosco Y, Fracassi E, Ortolan A, Ferraioli M, Carriero A, Visalli E, Bixio R, Desiati F, Bergamini A, Pedrollo E, Doria A, Foti R, Carletto A. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Ther Adv Musculoskelet Dis. 2022;14: 1759720X221090310. doi:10.1177\/1759720X221090310.","DOI":"10.1177\/1759720X221090310"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0875","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10067-021-05957-4","article-title":"Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis","volume":"41","author":"Kiltz","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0880","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/kead598","article-title":"Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis","volume":"63","author":"Deodhar","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"10349","key":"10.1016\/j.autrev.2026.104039_bb0885","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0890","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/acr2.11669","article-title":"Upadacitinib in active non-radiographic axial spondyloarthritis: 1-year data from a double-blind, randomized, placebo-controlled, phase 3 Trial","volume":"6","author":"van den Bosch","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0895","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-024-03441-3","article-title":"Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study","volume":"27","author":"van den Bosch","year":"2025","journal-title":"Arthritis Res Ther"},{"issue":"10214","key":"10.1016\/j.autrev.2026.104039_bb0900","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb0905","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0910","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"van der Heijde","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0915","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13075-023-03128-1","article-title":"Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study","volume":"25","author":"Baraliakos","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0920","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0925","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10162","key":"10.1016\/j.autrev.2026.104039_bb0930","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0935","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keab543","article-title":"Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)","volume":"61","author":"Maksymowych","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104039_bb0940","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2022.04.007","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0945","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/msc.1802","article-title":"Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: a scoping literature review","volume":"21","author":"Jubber","year":"2023","journal-title":"Musculoskel Care"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb0950","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb0955","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0960","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3899\/jrheum.131289","article-title":"Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis","volume":"41","author":"van Denderen","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb0965","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104039_bb0970","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study","volume":"13","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb0975","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - the GO-EASY Study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb0980","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb0985","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.2008.103192","article-title":"Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials","volume":"69","author":"Sieper","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb0990","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb0995","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/jcm13030912","article-title":"Comparison of incidence or recurrence of anterior uveitis in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors","volume":"13","author":"Kwon","year":"2024","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb1000","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2026.104039_bb1005","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb1010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13075-021-02549-0","article-title":"Incidence of anterior uveitis in patients with axial spondyloarthritis treated with anti-TNF or anti-IL17A: a systematic review, a pairwise and network meta-analysis of randomized controlled trials","volume":"23","author":"Roche","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb1020","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/ard.2003.012450","article-title":"Infliximab in spondyloarthropathy associated with Crohn\u2019s disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations","volume":"63","author":"Generini","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb1025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-\u03b1 therapy for inflammatory rheumatic disease: a nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Joint Bone Spine"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb1030","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025122","article-title":"Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study","volume":"100","author":"Conigliaro","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"9317","key":"10.1016\/j.autrev.2026.104039_bb1035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.autrev.2026.104039_bb1040","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb1045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb1050","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb1055","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2\/3 PURSUIT Induction and Maintenance Studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb1075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104039_bb1080","article-title":"Certolizumab pegol for maintenance of medically induced remission in Crohn\u2019s disease","volume":"6(6):CD013747","author":"Okabayashi","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"10\u201311","key":"10.1016\/j.autrev.2026.104039_bb1085","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/00365521.2018.1519597","article-title":"Clinical effectiveness of golimumab in Crohn\u2019s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)","volume":"53","author":"Rundquist","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb1090","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb1095","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/apt.15370","article-title":"Increased risk of developing Crohn\u2019s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNF\u03b1 agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease","volume":"50","author":"Korzenik","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb1100","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb1105","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"18","key":"10.1016\/j.autrev.2026.104039_bb1110","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb1120","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb1125","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"26","key":"10.1016\/j.autrev.2026.104039_bb1130","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb1135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaad.2016.10.027","article-title":"Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb1140","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cpt.2155","article-title":"IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in vigibase","volume":"110","author":"Petitpain","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb1150","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1080\/09546634.2021.1890683","article-title":"PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines","volume":"33","author":"Belinch\u00f3n Romero","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"10.1016\/j.autrev.2026.104039_bb1155","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/09546634.2017.1402116","article-title":"A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis","volume":"29","author":"No","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"10235","key":"10.1016\/j.autrev.2026.104039_bb1160","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"IB","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb1170","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","article-title":"Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy","volume":"12","author":"Rudwaleit","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb1175","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","article-title":"Efficacy in current practice of switching between anti-tumour necrosis factor- \u03b1 agents in spondyloarthropathies","volume":"50","author":"Paccou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","article-title":"Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register","volume":"70","author":"Lie","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104039_bb1185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13075-016-0969-2","article-title":"Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss clinical quality management cohort","volume":"18","author":"Ciurea","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.autrev.2026.104039_bb1190","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/annrheumdis-2019-215934","article-title":"Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort","volume":"79","author":"Micheroli","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb1195","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104039_bb1200","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1205","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb1210","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb1215","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb1220","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10142","key":"10.1016\/j.autrev.2026.104039_bb1225","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104039_bb1230","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.220353","article-title":"Etanercept withdrawal and retreatment in nonradiographic axial spondyloarthritis: Results of RE-EMBARK, an open-label phase IV trial","volume":"50","author":"van den Bosch","year":"2023","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104039_bb1235","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1093\/rheumatology\/kead112","article-title":"Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)","volume":"62","author":"Weinstein","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb1240","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2026.104039_bb1245","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104039_bb1250","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00393-022-01226-0","article-title":"Is tapering or discontinuation of biologic treatment in patients with radiographic and nonradiographic axial spondyloarthritis reasonable?\u202f: A local cohort study","volume":"83","author":"Harman","year":"2024","journal-title":"Z Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1255","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.autrev.2026.104039_bb1260","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","article-title":"Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review","volume":"55","author":"Navarro-Comp\u00e1n","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb1265","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/acr.24184","article-title":"Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Lawson","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2026.104039_bb1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109256","article-title":"Tapering biologics in axial spondyloarthritis: a systematic literature review","volume":"112","author":"Saoussen","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/ard-2022-223298","article-title":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Webers","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104039_bb1280","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1621313","article-title":"Efficacy of withdrawal or tapering of bDMARDs vs. standard regimen in axial spondyloarthritis patients: systematic review and meta-analysis informing the update of the Spanish Society of Rheumatology Guideline","volume":"12","author":"Park","year":"2025","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.autrev.2026.104039_bb1285","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb1290","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001108","article-title":"Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis","volume":"5","author":"L\u00f3pez-Medina","year":"2019","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.autrev.2026.104039_bb1295","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.semarthrit.2016.09.002","article-title":"Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis","volume":"46","author":"Sieper","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104039_bb1300","article-title":"Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?","volume":"1","author":"Baraliakos","year":"2015","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.autrev.2026.104039_bb1305","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3899\/jrheum.130588","article-title":"Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases?","volume":"40","author":"Wallis","year":"2013","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104039_bb1310","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard-2022-222731","article-title":"Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study","volume":"82","author":"Landew\u00e9","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:18:54Z","timestamp":1777130334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":262,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1568997226000534"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104039","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chinese recommendations for the diagnosis and management of non-radiographic axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104039"}}